IQWiG finds no hint of added benefit for Eylea in macular edema after BRVO

The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether German pharma major Bayer’s (BAYN: DE) ophthalmic drug Eylea (aflibercept) offers an added benefit over the appropriate comparator therapy.

Eylea has been available since February this year for patients with impaired vision due to macular edema that follows blockage of branch veins of the central retinal vein (branch retinal vein occlusion, BRVO). However, the IQWiG says that such an added benefit cannot be derived from the dossier because it contained no data relevant for the assessment.

Manufacturer considered only the comparison with ranibizumab to be adequate